303 related articles for article (PubMed ID: 31243183)
1. Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society.
Arima H; Iwama S; Inaba H; Ariyasu H; Makita N; Otsuki M; Kageyama K; Imagawa A; Akamizu T
Endocr J; 2019 Jul; 66(7):581-586. PubMed ID: 31243183
[TBL] [Abstract][Full Text] [Related]
2. [Endocrine Dysfunction Associated with Immune Checkpoint Blockade].
Iwama S
Gan To Kagaku Ryoho; 2020 Feb; 47(2):203-206. PubMed ID: 32381947
[TBL] [Abstract][Full Text] [Related]
3. Clinical Characteristics, Management, and Potential Biomarkers of Endocrine Dysfunction Induced by Immune Checkpoint Inhibitors.
Iwama S; Kobayashi T; Arima H
Endocrinol Metab (Seoul); 2021 Apr; 36(2):312-321. PubMed ID: 33934588
[TBL] [Abstract][Full Text] [Related]
4. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
Michot JM; Lazarovici J; Tieu A; Champiat S; Voisin AL; Ebbo M; Godeau B; Michel M; Ribrag V; Lambotte O
Eur J Cancer; 2019 Nov; 122():72-90. PubMed ID: 31634647
[TBL] [Abstract][Full Text] [Related]
5. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management.
Sznol M; Postow MA; Davies MJ; Pavlick AC; Plimack ER; Shaheen M; Veloski C; Robert C
Cancer Treat Rev; 2017 Jul; 58():70-76. PubMed ID: 28689073
[TBL] [Abstract][Full Text] [Related]
6. Endocrine side effects induced by immune checkpoint inhibitors.
Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics and potential biomarkers of thyroid and pituitary immune-related adverse events.
Kobayashi T; Iwama S; Arima H
Endocr J; 2024 Jan; 71(1):23-29. PubMed ID: 37940567
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society.
Kwon H; Roh E; Ahn CH; Kim HK; Ku CR; Jung KY; Lee JH; Kim EH; Suh S; Hong S; Ha J; Moon JS; Kim JH; Kim MK;
Endocrinol Metab (Seoul); 2022 Dec; 37(6):839-850. PubMed ID: 36604955
[TBL] [Abstract][Full Text] [Related]
9. Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know).
Ruggeri RM; Campennì A; Giuffrida G; Trimboli P; Giovanella L; Trimarchi F; Cannavò S
J Endocrinol Invest; 2019 Jul; 42(7):745-756. PubMed ID: 30471004
[TBL] [Abstract][Full Text] [Related]
10. Endocrine sequelae of immune checkpoint inhibitors.
Ntali G; Kassi E; Alevizaki M
Hormones (Athens); 2017 Oct; 16(4):341-350. PubMed ID: 29518754
[TBL] [Abstract][Full Text] [Related]
11. Pituitary and adrenal disorders induced by immune checkpoint inhibitors.
Albarel F; Brue T; Castinetti F
Ann Endocrinol (Paris); 2023 May; 84(3):339-345. PubMed ID: 36965852
[TBL] [Abstract][Full Text] [Related]
12. Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review.
Stelmachowska-Banaś M; Czajka-Oraniec I
Endocr Connect; 2020 Oct; 9(10):R207-R228. PubMed ID: 33064663
[TBL] [Abstract][Full Text] [Related]
13. Endocrine disorders.
Montgomery DA; Harley JM
Clin Obstet Gynaecol; 1977 Aug; 4(2):339-70. PubMed ID: 340105
[No Abstract] [Full Text] [Related]
14. Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors.
Kurimoto C; Inaba H; Ariyasu H; Iwakura H; Ueda Y; Uraki S; Takeshima K; Furukawa Y; Morita S; Yamamoto Y; Yamashita S; Katsuda M; Hayata A; Akamatsu H; Jinnin M; Hara I; Yamaue H; Akamizu T
Cancer Sci; 2020 May; 111(5):1468-1477. PubMed ID: 32086984
[TBL] [Abstract][Full Text] [Related]
15. Check point inhibitors and autoimmunity: Why endocrinopathies and who is prone to?
Percik R; Shoenfeld Y
Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101411. PubMed ID: 32278687
[TBL] [Abstract][Full Text] [Related]
16. Clinical diagnosis and treatment of immune checkpoint inhibitors-related endocrine dysfunction.
Duan L; Wang L; Wang H; Si X; Zhang L; Liu X; Li Y; Guo X; Zhou J; Zhu H; Zhang L
Thorac Cancer; 2020 Apr; 11(4):1099-1104. PubMed ID: 32043816
[TBL] [Abstract][Full Text] [Related]
17. Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management.
Barroso-Sousa R; Ott PA; Hodi FS; Kaiser UB; Tolaney SM; Min L
Cancer; 2018 Mar; 124(6):1111-1121. PubMed ID: 29313945
[TBL] [Abstract][Full Text] [Related]
18. The changing clinical spectrum of endocrine adverse events in cancer immunotherapy.
Chiloiro S; Bianchi A; Giampietro A; Milardi D; De Marinis L; Pontecorvi A
Trends Endocrinol Metab; 2022 Feb; 33(2):87-104. PubMed ID: 34895977
[TBL] [Abstract][Full Text] [Related]
19. [Endocrine side effects of cancer immunotherapy].
Kroiß M; Schilling B; Deutschbein T
Dtsch Med Wochenschr; 2020 Dec; 145(24):1736-1741. PubMed ID: 33254246
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review.
Joshi MN; Whitelaw BC; Palomar MT; Wu Y; Carroll PV
Clin Endocrinol (Oxf); 2016 Sep; 85(3):331-9. PubMed ID: 26998595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
